Mcneil-ppc, Inc.

Transform Pharmaceuticals, Inc.

University of South Florida

Janssen Biotech, Inc.

Janssen R&d Ireland

Janssen Sciences Ireland Uc

Mark Tawa

Julius F Remenar

Örn Almarsson

Alexey Popov

Hongming Chen

Matthew Lynn Peterson

Orn Almarsson

Hector Guzman

Lieven Elvire Colette Baert

Michael John Zaworotko

Magali Bourghol Hickey

Mark Oliveira

Michael MacPhee

Tanise Shattock

Jihad B Saoud

Thomas J L Rammeloo

Matthew F Sansone

Lieven Elvire Baert

Etravirine (TMC125) nicotinamide co-crystal, its preparation, and use in the treatment of HIV infection.

Co-crystal of etravirine and nicotinamide

The invention relates to pharmaceutical compositions comprising propylene glycol solvates of APIs.

Pharmaceutical propylene glycol solvate compositions

Crystalline salts, polymorphs, solvates, and hydrates of bicalutamide, 5-fluorouracil, donepezil, anastrozole, nelfinavir, mirtazapine, lansoprazole, and tamsulosin, or derivatives thereof are provided by the subject invention. Methods of making and using the same are also provided.

Pharmaceutical forms, and methods of making and using the same

Hydrated celecoxib sodium salt forms and processes to prepare hydrated celecoxib sodium salt forms are disclosed. The celecoxib sodium salt forms are particularly useful and suitable for pharmaceutical applications.

Hydrated sodium salt form of celecoxib

The invention relates to methods of screening mixtures containing a pharmaceutical compound and an excipient to identify properties of the pharmaceutical compound/excipient combination that retard solid-state nucleation. The invention further relates to increasing the solubility, dissolution and bioavailability of a drug with low solubility in gastric fluids conditions by combining the drug with a precipitation retardant and an optional enhancer.

Pharmaceutical compositions with improved dissolution

Disclosed herein is a novel sulfate salt of tianeptine with improved properties. Also described herein are novel pharmaceutical compositions comprising tianeptine sulfate salt, methods of making, and related methods of treatment.

Tianeptine sulfate salt forms and methods of making and using the same

The invention relates to pharmaceutical compositions comprising propylene glycol solvates of APIs. In particular a 2:1 complex of naproxen sodium to propylene glycol is disclosed which is a crystalline solid. The complex is prepared by crystallization of a mixture of naproxen sodium and propylene glycol from diethyl ether. It is identifiable by its X-ray powder diffraction pattern described herein.

Pharmaceutically acceptable propylene glycol solvate of naproxen

An acid salt of sertraline, wherein the acid is citric acid, fumaric acid, malic acid, maleic acid, malonic acid, phosphoric acid, succinic acid, sulfuric acid, L-tartaric acid, HBr, acetic acid, benzoic acid, benzenesulfonic acid, ethanesulfonic acid, lactic acid, methanesulfonic acid or toluenesulfonic acid. Similarly, a solvate of sertraline HCl, wherein the solvent is methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, t-butanol, acetic acid, ethyl acetate, or propylene glycol.

Sertraline compositions

Growing community of inventors

Acton, MA, United States of America

Mark Tawa